Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus

NCT02889510 on ClinicalTrials.gov · last registry update 2021-02-26

A small phase 3 — 76 participants, against a typical 424. The sponsor logged completion for 18 November 2019. Primary outcome, as filed: Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Lecube, Albert, M.D.
Sponsor type: Indiv
Enrollment: 76
Started: 2016-10-04
Primary completion: 2019-11-18 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.